Background/Purpose: Aeromonas infections, rarely reported in Western countries, are not uncommon infectious diseases in Taiwan. The clinical manifestations and prognostic factors of Aeromonas spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis were investigated. Methods: We reviewed the medical charts and microbiological records of liver cirrhosis patients with Aeromonas SBP between January 1990 and December 2005, in a medical center in southern Taiwan. Results: Thirty-one liver cirrhosis patients developed Aeromonas SBP within a 16-year period. The majority (26, 84%) had concurrent Aeromonas bacteremia. A. sobria (55%) and A. hydrophila (45%) were the causative species. The predominant clinical manifestations included fever (84%), abdominal pain (74%), hypotension on admission (48%), altered mental status (45%), and acute renal failure (42%). Gram-negative bacilli were found in Gram staining of ascitic fluids in 27% of 26 patients, while aeromonads were isolated from ascitic fluids in 55% of 31 patients. The yield rate of ascitic fluid cultures decreased greatly, if paracentesis was performed at > 3 hours after the administration of antimicrobial therapy. All but one patient received in-vitro-active antimicrobial agents within 48 hours, but the all-cause mortality rate was 56%. Initial high Pitt's bacteremia score was independently associated with a fatal outcome in multivariate analysis. Conclusion: Aeromonas SBP is a fatal disease, and must be included in the differential diagnosis of SBP in patients with advanced liver cirrhosis in endemic areas. [J Formos Med Assoc 2009;108(4):293-300] 
ORIGINAL ARTICLE
Aeromonas species are oxidase-producing Gramnegative rods and aquatic microorganisms, and have been implicated in a variety of human diseases. They have been isolated from chlorinated and fresh water, and are ubiquitous in fresh water, fish and shellfish, meats, and fresh vegetables. 1 The reported routes of entry for Aeromonas species include oral consumption of contaminated food 1 or exposure of wounds to environmental sources that contain aeromonads. 2 The spectrum of Aeromonas infections in humans has expanded, and includes acute gastroenteritis, hepatobiliary tract infections, peritonitis, pneumonia, empyema, meningitis, endocarditis, and skin and soft tissue infections. [2] [3] [4] [5] Among these, peritonitis is an uncommon yet serious Aeromonas infection, which presents in three distinct clinical settings: spontaneous bacterial peritonitis (SBP), peritonitis in chronic ambulatory peritoneal dialysis, or intestinal perforation.
Escherichia coli is the most common organism that causes SBP, and is responsible for 40-63% of cases. [6] [7] [8] [9] [10] In Taiwan, major pathogens are E. coli
and Klebsiella pneumoniae, which altogether account for 71% of isolates. 11 However, it has been recognized that patients with liver cirrhosis are susceptible to invasive Aeromonas infections, 2, 12, 13 and such a clinical association is especially evident in southern Taiwan. We have reported that 54% of 104 cases of monomicrobial Aeromonas bacteremia had liver cirrhosis, and the mortality rate was 39% among the latter patients. 13 Moreover, Aeromonas species are responsible for 14.2% of Gram-negative-bacillus bacteremia in liver cirrhosis patients in Taiwan. 14 Clinical cases of Aeromonas SBP have also been occasionally encountered in Taiwan, 12, 13, 15 Korea, 10 Spain, [16] [17] [18] and northern Europe. 19 Few studies have focused on clinical aspects of Aeromonas SBP in patients with liver cirrhosis. We investigated the clinical manifestations and prognostic factors of Aeromonas SBP in liver cirrhosis patients.
Methods
The medical charts and microbiological records of liver cirrhosis patients with Aeromonas SBP in National Cheng Kung University Hospital, a university-affiliated medical center with approximately 900 beds in Tainan, Taiwan, were collected between January 1990 and December 2005. Gramnegative bacilli isolated from blood or ascitic fluid were identified as Aeromonas species on the basis of the following findings: a positive oxidase reaction, no growth on thiosulfate/citrate/sucrose agar, growth on MacConkey agar, and resistance to vibriostatic compound O/129 (150 μg). Biochemical profiles of the API system (BioMerieux, Marcy-I'Etoile, France) were utilized for identification of aeromonads to the species level. The KirbyBauer disk-diffusion method was used for in vitro susceptibility testing. Antibiotics tested included ampicillin/sulbactam, cephalosporins (cephalothin, cefuroxime, ceftriaxone), aminoglycosides (amikacin, gentamicin), and fluoroquinolones (norfloxacin, lomefloxacin, levofloxacin, ofloxacin). The breakpoint zone for susceptibility or resistance followed the recommendations of the Clinical and Laboratory Standards Institute for Enterobacteriaceae. 20 According to the consensus of the International Ascites Club, diagnosis of SBP is based on an ascitic fluid polymorphonuclear leukocyte count ≥ 250/mm 3 by diagnostic paracentesis, and exclusion of secondary peritonitis. 21 The demographic data, underlying diseases, place of acquisition of infection, history of consumption of seafood or un/undercooked food, wound exposure to soil or water, initial presentations, laboratory parameters, microbiological reports, antimicrobial susceptibility, time to perform paracentesis in relation to initiation of in-vitro-active antimicrobial therapy, clinical course and outcome of eligible cases were collected. The Child-Pugh classification was used to evaluate the degree of hepatic decompensation in patients with liver cirrhosis. 22 The severity of acute illness at the onset of Aeromonas infections was assessed by Pitt's bacteremia score, calculated within 1 day after hospital admission, a previously validated scoring system that was based on mental status, body temperature, blood pressure, requirement for mechanical ventilation, and recent cardiac arrest. 23 Hypotension was defined as low systolic blood pressure (< 90 mmHg) or the need for inotropic agents to maintain blood pressure. Acute renal failure was defined as an increment of serum creatinine about 0.5 mg/dL from baseline in patients with baseline level < 3.0 mg/dL, or an increment of 1.0 mg/dL in patients with baseline creatinine level > 3.0 mg/dL. Critical illness was defined as that described by Pitt with a bacteremia score of ≥ 4 points. Time to defervescence was defined as the period between the initiation of antimicrobial therapy and the first day of 3 consecutive days with a sustained body temperature < 37°C. 
Etiological pathogens
The results of ascitic fluid culture were available for all patients. Of 30 patients in whom blood culture was performed, 26 (87%) had concurrent Aeromonas bacteremia. A. sobria and A. hydrophila were the causative organisms, accounting for 55% (17 cases) and 45% (14), respectively. Overall, 54% and 61% of Aeromonas isolates were susceptible to cephalothin and cefuroxime, respectively. Cefotaxime, gentamicin, amikacin and levofloxacin were active in vitro against all isolates tested. [31] 180 ± 282 (35-1616) ALT (IU/L) [31] 85 ± 87 (20-391) Total bilirubin (mg/dL) [31] 11 ± 10 (2-51) Albumin (g/dL) [30] 2.5 ± 0.5 (1.8-3.7) Prolongation of prothrombin 7.9 ± 6.6 (0. [31] 12,548 ± 17,854 (271-67,860) % of neutrophils [31] 90 ± 8 (58-98) Total protein (mg/dL) [25] 1245 ± 866 (107-3420) Glucose (mg/dL) [17] 85 ± 82 (17-271) 
Clinical features

Microbiological studies
Gram staining of ascitic fluid disclosed Gramnegative bacilli in 7 (27%) of 26 cases, while aeromonads could be isolated from 17 (55%) of 31 cases. The microbiological data from peritoneal fluid were further categorized into a pretreatment group (peritoneal fluid obtained prior to antimicrobial therapy) and posttreatment group (fluid obtained after initiation of effective antimicrobial therapy). In both groups, the yield rate of Gram staining of ascites was similar (5/17, 29% in the pretreatment group vs. 2/9, 22% in the posttreatment group; p = 0.69). However, the isolation rate of ascitic fluid culture was higher in the pretreatment group (14/21, 67% vs. 3/10, 30% in the posttreatment group; p = 0.055). Of note, bacterial cultures of ascitic fluid obtained within 3 hours after antimicrobial therapy in three patients were all positive, while those obtained more than 3 hours after antimicrobial therapy in seven patients were all negative (p = 0.002). In one patient in whom ascitic fluid was obtained 13 hours after in-vitro-active antimicrobial therapy, Gram staining remained positive, while the culture was sterile.
Treatment and clinical outcome
All but one case of Aeromonas SBP received at least a parenteral antibiotic within 48 hours of a diagnosis of peritonitis. The exception was a case of Child C liver cirrhosis with Aeromonas SBP, which spontaneously resolved without antimicrobial therapy. In the initial 3 days of empirical therapy, 25 (81%) cases received an in-vitro-active drug (22 cases with ceftriaxone or cefotaxime, and one each with cefuroxime, fluoroquinolone or aminoglycoside); four (13%) received combination therapy with an in-vitro-active cephalosporin and aminoglycoside; and one was treated with ineffective cefazolin. Overall, 24 (77%) cases were treated by a third-generation cephalosporin (ceftriaxone or cefotaxime) as initial empirical treatment. Comparing cases treated with one or two effective drugs, there was no significant difference in all-cause mortality rate at 3 days (50% vs. 59%; p = 0.62) or 2 weeks (40% vs. 50%; p = 0.73). All-cause mortality rate at 2 weeks among cases receiving empirical cefotaxime or ceftriaxone therapy was not significantly different from that of cases receiving other drugs (37% vs. 57%; p = 0.35). Overall, the all-cause mortality rate at 3 days and 2 weeks and inhospital mortality rate were 38% (12 cases), 41% (13 cases), and 56% (18 cases), respectively. Mean duration of hospitalization before death in 18 fatal cases was 7.6 ± 8.4 days (range, 1-30 days). Of 13 surviving cases, mean time to defervescence was 2.1 ± 1.6 days (range, 0-5 days), and mean hospital stay was 14.1 ± 11.0 days (range, 3-43 days).
By univariate analysis, significant risk factors for all-cause fatality at 2 weeks included an initial high Pitt bacteremic score, high Pugh score, altered mental status, hypotension, upper gastrointestinal bleeding, acute renal failure, elevated levels of serum aminotransferases, and prolongation of prothrombin time (Table 2) . Bacteremic cases had a higher mortality rate than non-bacteremic cases, although the difference was not statistically significant (13/26, 50% vs. 0/4, 0%; p = 0.06). Presence of abdominal pain or rebound tenderness, or absence of fever were not associated with poor prognosis. Besides, none of age, sex, place of acquisition of infection, underlying hepatocellular carcinoma or diabetes mellitus, Aeromonas species, blood leukocyte or platelet counts, serum albumin levels, ascitic leukocyte count, or bacterial growth in ascitic fluid, was significantly associated with a grave prognosis. By multivariate analysis, only a Pitt bacteremic score of ≥ 4 points was significantly associated with fatality at 2 weeks. Taipei, a city located in northern Taiwan. 24 Although a history of oral consumption of seafood or undercooked food could not be traced in our patients, it is likely that aeromonads can be encountered in the environment, not only in seafood but also in drinking water. Second, the prevalence of individuals with chronic liver diseases and liver cirrhosis, who are susceptible to invasive Aeromonas infections, is high in Taiwan, as 15-20% of the general population here has chronic hepatitis B infection, 25 and 2.9-5.4%
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has hepatitis C. 26 Therefore, in Taiwan In general, clinical manifestations and disease severity of SBP vary greatly, and patients can be symptomatic and critically ill, slightly symptomatic, or even asymptomatic. 8, 29, 30 In our study, Aeromonas SBP mainly developed in subjects with decompensated liver cirrhosis, as demonstrated by the fact that 90% of cases were classified as Child-Pugh C. Not surprisingly, fever and abdominal pain were the prominent presentations. Moreover, such an infection was an acute and severe illness, often presenting with fever and chills initially, and urged the affected individuals to attend the hospital within 24 hours after the onset of relevant symptoms. Nearly half of the cases experienced shock and altered mental status at admission, and were considered as having critical conditions, as suggested by high Pitt bacteremic scores. Although cases of SBP usually experienced abdominal discomfort, 25% and 75% of our patients had no abdominal pain or rebounding tenderness, respectively. Furthermore, the clinical triad of peritonitis, i.e. fever, abdominal pain and rebounding tenderness, was found only in 19% of cases, which was less than the 40% mentioned in a study in Singapore. 30 As a result, not all patients with SBP fulfilled the clinical triad, which indicates the difficulty and complexity of clinical diagnosis of SBP. Moreover, Aeromonas SBP was indistinguishable from that caused by other enteric organisms. Thus, the accuracy of microbiological identification by a clinical microbiological laboratory is indispensable for the diagnosis of Aeromonas SBP. As expected in the cases of SBP caused by other Gram-negative bacilli, increasing polymorphonuclear leukocytes and protein concentrations in ascitic fluid were present in Aeromonas SBP. However, the yield rate of ascitic cultures was related to the timing of antimicrobial therapy. In ascitic fluid collected before administration of therapy, the yield rate of bacterial cultures was higher than that obtained after initialization of therapy (67% vs. 30%; p = 0.055). Moreover, cultures of ascitic fluid obtained 3 hours after antimicrobial therapy were sterile. As for Gram staining, the result was less influenced by the timing of antimicrobial therapy. Therefore, it is preferable to perform paracentesis before or immediately after initiation of antimicrobial therapy, and microbiological cultures and Gram staining are of value in establishing the diagnosis of SBP.
The reported inhospital mortality rates of SBP, mostly caused by Enterobacteriaceae, are 12-42.2%. 6, 8, [29] [30] [31] [32] Likewise, the mortality rate of SBP caused by E. coli, the most common etiological agent, is 20-44.4%. 33 In contrast, in the present study, Aeromonas SBP led to a higher mortality rate (56%), similar to the 50% reported by Huang et al. 15 The poor prognosis of Aeromonas infections was in accordance with the findings of our earlier work. In a comparative experiment, a higher pathogenicity of A. hydrophila was indicated by higher degrees of cytokine production, and more rapid and intense inflammatory reactions in affected muscles in a mouse model, compared with that of E. coli or K. pneumoniae isolates. 34 Cefotaxime, a third-generation cephalosporin with excellent penetration into ascites and without nephrotoxicity, is the best-studied drug for SBP. 35 However, there is in vivo evidence of emergence of antimicrobial resistance during cefotaxime therapy in cases of cefotaxime-susceptible Aeromonas infections. 13, 36 Cefotaxime and minocycline have been demonstrated to act synergistically against A. hydrophila in a murine model, 37 and ciprofloxacin is at least as effective as cefotaxime-minocycline combination for murine A. hydrophila infections. 38 As a result, antimicrobial therapy with a fluoroquinolone or combination of a third-generation cephalosporin and a tetracycline analog are plausible alternatives for systemic Aeromonas infections, but further study is warranted. In summary, clinicians should be highly alert when cirrhosis patients with ascites present with fever, abdominal pain, altered consciousness or shock, which may be initial manifestations of SBP. Prompt paracentesis should be performed for early detection of SBP, and antimicrobial therapy should be given before or immediately after the sampling of blood and ascitic fluid. Aeromonas SBP, although rare, is a fatal infectious disease in patients with advanced liver cirrhosis. In endemic areas, empirical antimicrobial therapy should cover aeromonads for critically ill patients with SBP.
